The nature of self for T cells-a systems-level perspective

Current Opinion in Immunology

Volumn 34, Issue , 2015, Pages 1-8

  Granados, Diana P ^a,b   Laumont, Céline M ^a,b   Thibault, Pierre ^a,b   Perreault, Claude ^a,b  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMINOGLYCOSIDE; CARBAMAZEPINE; CRYPTIC MAJOR HISTOCOMPATIBILITY ANTIGEN; GAMMA INTERFERON; IMMUNOPEPTIDOME; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEOME; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIGEN;

ANTIGEN FUNCTION; CD8+ T LYMPHOCYTE; CELL LINEAGE; CELL MATURATION; HUMAN; IMMUNOREGULATION; INFLAMMATION; LYMPHOCYTE FUNCTION; MASS SPECTROMETRY; METABOLISM; MOLECULAR BIOLOGY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEOGENOMICS; REVIEW; RNA SEQUENCE; T LYMPHOCYTE; VIRUS INFECTION; ANIMAL; ANTIGEN PRESENTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; INFECTION; PROTEOMICS;

ANIMALS; ANTIGEN PRESENTATION; AUTOANTIGENS; HUMANS; INFECTION; INFLAMMATION; PROTEOMICS; SELF TOLERANCE; T-LYMPHOCYTES;

EID: 84918582017     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2014.10.012     Document Type: Review

References (80)

1. Davis M.M., Krogsgaard M., Huse M., Huppa J., Lillemeier B.F., Li Q.J. T cells as a self-referential, sensory organ. Annu Rev Immunol 2007, 25:681-695.
2. Mandl J.N., Monteiro J.P., Vrisekoop N., Germain R.N. T cell-positive selection uses self-ligand binding strength to optimize repertoire recognition of foreign antigens. Immunity 2013, 38:263-274.
3. Anton L.C., Yewdell J.W. Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors. J Leukoc Biol 2014, 95:551-562.
4. Kim W., Bennett E.J., Huttlin E.L., Guo A., Li J., Possemato A., Sowa M.E., Rad R., Rush J., Comb M.J., Harper J.W., Gygi S.P. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 2011, 44:325-340.
5. Yewdell J.W. DRiPs solidify: progress in understanding endogenous MHC class I antigen processing. Trends Immunol 2011, 32:548-558.
6. Baboo S., Bhushan B., Jiang H., Grovenor C.R., Pierre P., Davis B.G., Cook P.R. Most human proteins made in both nucleus and cytoplasm turn over within minutes. PLoS One 2014, 9:e99346.
7. Rock K.L., Farfan-Arribas D.J., Colbert J.D., Goldberg A.L. Re-examining class-I presentation and the DRiP hypothesis. Trends Immunol 2014, 35:144-152.
8. Reits E.A., Hodge J.W., Herberts C.A., Groothuis T.A., Chakraborty M., Wansley E., Camphausen K., Luiten R.M., de Ru A.H., Neijssen J., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271.
9. + T cell cross-priming via transfer of proteasome substrates. Science 2004, 304:1318-1321.
10. Mester G., Hoffmann V., Stevanovic S. Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands. Cell Mol Life Sci 2011, 68:1521-1532.
11. Nagaraj N., Wisniewski J.R., Geiger T., Cox J., Kircher M., Kelso J., Paabo S., Mann M. Deep proteome and transcriptome mapping of a human cancer cell line. Mol Syst Biol 2011, 7:548.
12. Beck M., Schmidt A., Malmstroem J., Claassen M., Ori A., Szymborska A., Herzog F., Rinner O., Ellenberg J., Aebersold R. The quantitative proteome of a human cell line. Mol Syst Biol 2011, 7:549.
13. Bourdetsky D., Schmelzer C.E., Admon A. The nature and extent of contributions by defective ribosome products to the HLA peptidome. Proc Natl Acad Sci U S A 2014, 111:E1591-E1599.
14. Hassan C., Kester M.G., de Ru A.H., Hombrink P., Drijfhout J.W., Nijveen H., Leunissen J.A., Heemskerk M.H., Falkenburg J.H., van Veelen P.A. The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics 2013, 12:1829-1843.
15. Mommen G.P., Frese C.K., Meiring H.D., van Gaans-van den Brink J., de Jong A.P., van Els C.A., Heck A.J. Expanding the detectable HLA peptide repertoire using electron-transfer/higher-energy collision dissociation (EThcD). Proc Natl Acad Sci U S A 2014, 111:4507-4512.
16. Berlin C., Kowalewski D.J., Schuster H., Mirza N., Walz S., Handel M., Schmid-Horch B., Salih H.R., Kanz L., Rammensee H.G., Stevanovic S., Stickel J.S. Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach towards peptide based immunotherapy. Leukemia 2014, [Epub ahead of print]. 10.1038/leu.2014.233.
17. Fortier M.H., Caron E., Hardy M.P., Voisin G., Lemieux S., Perreault C., Thibault P. The MHC class I peptide repertoire is molded by the transcriptome. J Exp Med 2008, 205:595-610.
18. Granados D.P., Sriranganadane D., Daouda T., Zieger A., Laumont C.M., Caron-Lizotte O., Boucher G., Hardy M.P., Gendron P., CÔté C., et al. Impact of genomic polymorphism on the repertoire of human MHC class I-associated peptides. Nat Commun 2014, 5:3600.
19. Hoof I., van Baarle D., Hildebrand W.H., Kesmir C. Proteome sampling by the HLA class I antigen processing pathway. PLoS Comput Biol 2012, 8:e1002517.
20. Dudek N.L., Tan C.T., Gorasia D.G., Croft N.P., Illing P.T., Purcell A.W. Constitutive and inflammatory immunopeptidome of pancreatic beta-cells. Diabetes 2012, 61:3018-3025.
21. Vincent K., Hardy M.P., Trofimov A., Laumont C.M., Sriranganadane D., Hadj-Mimoune S., Fourati I.S., Soudeyns H., Thibault P., Perreault C. Rejection of leukemic cells requires antigen-specific T cells with high functional avidity. Biol Blood Marrow Transplant 2014, 20:37-45.
22. Paul S., Weiskopf D., Angelo M.A., Sidney J., Peters B., Sette A. HLA class I alleles are associated with peptide-binding repertoires of different size, affinity and immunogenicity. J Immunol 2013, 191:5831-5839.
23. Milner E., Barnea E., Beer I., Admon A. The turnover kinetics of MHC peptides of human cancer cells. Mol Cell Proteomics 2006, 5:357-365.
24. Croft N.P., Smith S.A., Wong Y.C., Tan C.T., Dudek N.L., Flesch I.E.A., Tscharke D.C., Purcell A.W. Kinetics of antigen expression and epitope presentation during virus infection. PLoS Pathog 2013, 9:e1003129.
25. Goodenough E., Robinson T.M., Zook M.B., Flanigan K.M., Atkins J.F., Howard M.T., Eisenlohr L.C. Cryptic MHC class I-binding peptides are revealed by aminoglycoside-induced stop codon read-through into the 3'UTR. Proc Natl Acad Sci U S A 2014, 111:5670-5675.
26. Boisvert F.M., Ahmad Y., Gierlinski M., Charriere F., Lamont D., Scott M., Barton G., Lamond A.I. A quantitative spatial proteomics analysis of proteome turnover in human cells. Mol Cell Proteomics 2012, 11:M111.
27. Qian S.-B., Reits E., Neefjes J., Deslich J.M., Bennink J.R., Yewdell J.W. Tight linkage between translation and MHC class I peptide ligand generation implies specialized antigen processing for defective ribosomal products. J Immunol 2006, 177:227-233.
28. Apcher S., Daskalogianni C., Lejeune F., Manoury B., Imhoos G., Heslop L. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci U S A 2011, 108:11572-11577.
29. Granados D.P., Yahyaoui W., Laumont C.M., Daouda T., Muratore-Schroeder T.L., Cote C., Laverdure J.P., Lemieux S., Thibault P., Perreault C. MHC I-associated peptides preferentially derive from transcripts bearing miRNA response elements. Blood 2012, 119:e181-e191.
30. Gu W., Cochrane M., Leggatt G.R., Payne E., Choyce A., Zhou F., Tindle R., McMillan N.A.J. Both treated and untreated tumors are eliminated by short hairpin RNA-based induction of target-specific immune responses. Proc Natl Acad Sci U S A 2009, 106:8314-8319.
31. de Verteuil D., Muratore-Schroeder T.L., Granados D.P., Fortier M.H., Hardy M.P., Bramoullé A., Caron E., Vincent K., Mader S., Lemieux S., Thibault P., Perreault C. Deletion of immunoproteasome subunits imprints on the transcriptome and has a broad impact on peptides presented by major histocompatibility complex I molecules. Mol Cell Proteomics 2010, 9:2034-2047.
32. Adamopoulou E., Tenzer S., Hillen N., Klug P., Rota I.A., Tietz S., Gebhardt M., Stevanovic S., Schild H., Tolosa E., Melms A., Stoeckle C. Exploring the MHC-peptide matrix of central tolerance in the human thymus. Nat Commun 2013, 4:2039.
33. Caron E., Vincent K., Fortier M.H., Laverdure J.P., Bramoullé A., Hardy M.P., Voisin G., Roux P., Lemieux S., Thibault P., Perreault C. The MHC I immunopeptidome conveys to the cell surface an integrative view of cellular regulation. Mol Syst Biol 2011, 7:533.
34. Granados D.P., Tanguay P.L., Hardy M.P., Caron E., De Verteuil D., Meloche S., Perreault C. ER stress affects processing of MHC class I-associated peptides. BMC Immunol 2009, 10:10.
35. Neefjes J., Jongsma M.L.M., Paul P., Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011, 11:823-836.
36. English L., Chemali M., Duron J., Rondeau C., Laplante A., Gingras D., Alexander D., Leib D., Norbury C., Lippé R., Desjardins M. Autophagy enhances the presentation of endogenous viral antigens on MHC class I molecules during HSV-1 infection. Nat Immunol 2009, 10:480-487.
37. Kincaid E.Z., Che J.W., York I., Escobar H., Reyes-Vargas E., Delgado J.C., Welsh R.M., Karow M.L., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Rock K.L. Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 2012, 13:129-135.
38. Morandi F., Di C.E., Ferrone S., Petretto A., Pistoia V., Airoldi I. IL-27 in human secondary lymphoid organs attracts myeloid dendritic cells and impairs HLA class I-restricted antigen presentation. J Immunol 2014, 192:2634-2642.
39. Hansen T.H., Bouvier M. MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 2009, 9:503-513.
40. Hickman H.D., Luis A.D., Bardet W., Buchli R., Battson C.L., Shearer M.H., Jackson K.W., Kennedy R.C., Hildebrand W.H. Cutting edge: class I presentation of host peptides following HIV infection. J Immunol 2003, 171:22-26.
41. Wahl A., Schafer F., Bardet W., Hildebrand W.H. HLA class I molecules reflect an altered host proteome after influenza virus infection. Hum Immunol 2010, 71:14-22.
42. Illing P.T., Vivian J.P., Purcell A.W., Rossjohn J., McCluskey J. Human leukocyte antigen-associated drug hypersensitivity. Curr Opin Immunol 2013, 25:81-89.
43. Starck S.R., Shastri N. Non-conventional sources of peptides presented by MHC class I. Cell Mol Life Sci 2011, 68:1471-1479.
44. Steen H., Mann M. The ABC's (and XYZ's) of peptide sequencing. Nat Rev Mol Cell Biol 2004, 5:699-711.
45. Woo S., Cha S.W., Merrihew G., He Y., Castellana N., Guest C., MacCoss M., Bafna V. Proteogenomic database construction driven from large scale RNA-seq data. J Proteome Res 2014, 13:21-28.
46. Branca R.M., Orre L.M., Johansson H.J., Granholm V., Huss M., Perez-Bercoff A., Forshed J., Kall L., Lehtio J. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat Methods 2014, 11:59-62.
47. Warren E.H., Zhang X.C., Li S., Fan W., Storer B.E., Chien J.W., Boeckh M.J., Zhao L.P., Martin P.J., Hansen J.A. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood 2012, 120:2796-2806.
48. Spierings E., Hendriks M., Absi L., Canossi A., Chhaya S., Crowley J., Dolstra H., Eliaou J.F., Ellis T., Enczmann J., et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genet 2007, 3:e103.
49. Vincent K., Roy D.C., Perreault C. Next-generation leukemia immunotherapy. Blood 2011, 118:2951-2959.
50. Hombrink P., Hassan C., Kester M.G., de Ru A.H., van Bergen C.A., Nijveen H., Drijfhout J.W., Falkenburg J.H., Heemskerk M.H., van Veelen P.A. Discovery of T cell epitopes implementing HLA-peptidomics into a reverse immunology approach. J Immunol 2013, 190:3869-3877.
51. Fontaine P., Roy-Proulx G., Knafo L., Baron C., Roy D.C., Perreault C. Adoptive transfer of T lymphocytes targeted to a single immunodominant minor histocompatibility antigen eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001, 7:789-794.
52. Meunier M.C., Delisle J.S., Bergeron J., Rineau V., Baron C., Perreault C. T cells targeted against a single minor histocompatibility antigen can cure solid tumors. Nat Med 2005, 11:1222-1229.
53. + T cells. Blood 2010, 115:4923-4933.
54. Malarkannan S., Afkarian M., Shastri N. A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. J Exp Med 1995, 182:1739-1750.
55. Starck S.R., Jiang V., Pavon-Eternod M., Prasad S., McCarthy B., Pan T., Shastri N. Leucine-tRNA initiates at CUG start codons for protein synthesis and presentation by MHC class I. Science 2012, 336:1719-1723.
56. Ingolia N.T. Ribosome profiling: new views of translation, from single codons to genome scale. Nat Rev Genet 2014, 15:205-213.
57. Ingolia N.T., Brar G.A., Stern-Ginossar N., Harris M.S., Talhouarne G.J., Jackson S.E., Wills M.R., Weissman J.S. Ribosome profiling reveals pervasive translation outside of annotated protein-coding genes. Cell Rep 2014, 8:1365-1379.
58. Apcher S., Millot G., Daskalogianni C., Scherl A., Manoury B., Fahraeus R. Translation of pre-spliced RNAs in the nuclear compartment generates peptides for the MHC class I pathway. Proc Natl Acad Sci U S A 2013, 110:17951-17956.
59. David A., Dolan B.P., Hickman H.D., Knowlton J.J., Clavarino G., Pierre P., Bennink J.R., Yewdell J.W. Nuclear translation visualized by ribosome-bound nascent chain puromycylation. J Cell Biol 2012, 197:45-57.
60. Yewdell J.W., David A. Nuclear translation for immunosurveillance. Proc Natl Acad Sci U S A 2013, 110:17612-17613.
61. Weinzierl A.O., Maurer D., Altenberend F., Schneiderhan-Marra N., Klingel K., Schoor O., Wernet D., Joos T., Rammensee H.G., Stevanovic S. A cryptic vascular endothelial growth factor T-cell epitope: identification and characterization by mass spectrometry and T-cell assays. Cancer Res 2008, 68:2447-2454.
62. Popovic J., Li L.P., Kloetzel P.M., Leisegang M., Uckert W., Blankenstein T. The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed. Blood 2011, 118:946-954.
63. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., Samuels Y., Rosenberg S.A. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med 2013, 19:747-752.
64. Sewell A.K. Why must T cells be cross-reactive?. Nat Rev Immunol 2012, 12:669-677.
65. Castellana N., Bafna V. Proteogenomics to discover the full coding content of genomes: a computational perspective. J Proteomics 2010, 73:2124-2135.
66. Evans V.C., Barker G., Heesom K.J., Fan J., Bessant C., Matthews D.A. De novo derivation of proteomes from transcriptomes for transcript and protein identification. Nat Methods 2012, 9:1207-1211.
67. Restifo N.P., Dudley M.E., Rosenberg S.A. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol 2012, 12:269-281.
68. Galon J., Angell H.K., Bedognetti D., Marincola F.M. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013, 39:11-26.
69. Page D.B., Postow M.A., Callahan M.K., Allison J.P., Wolchok J.D. Immune modulation in cancer with antibodies. Annu Rev Med 2014, 65:185-202.
70. Andersen R.S., Thrue C.A., Junker N., Lyngaa R., Donia M., Ellebaek E., Svane I.M., Schumacher T.N., thor Straten P., Hadrup S.R. Dissection of T-cell antigen specificity in human melanoma. Cancer Res 2012, 72:1642-1650.
71. Kvistborg P., Shu C.J., Heemskerk B., Fankhauser M., Thrue C.A., Toebes M., van Rooij N., Linnemann C., van Buuren M.M., Urbanus J.H., et al. TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology 2012, 1:409-418.
72. Heemskerk B., Kvistborg P., Schumacher T.N. The cancer antigenome. EMBO J 2013, 32:194-203.
73. Hinrichs C.S., Restifo N.P. Reassessing target antigens for adoptive T-cell therapy. Nat Biotechnol 2013, 31:999-1008.
74. Coulie P.G., Van den Eynde B.J., van der Bruggen P., Boon T. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 2014, 14:135-146.
75. Rosenberg S.A. Finding suitable targets is the major obstacle to cancer gene therapy. Cancer Gene Ther 2014, 21:45-47.
76. van Rooij N., van Buuren M.M., Philips D., Velds A., Toebes M., Heemskerk B., van Dijk L.J., Behjati S., Hilkmann H., El A.D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol 2013, 31:e439-e442.
77. Lawrence M.S., Stojanov P., Mermel C.H., Robinson J.T., Garraway L.A., Golub T.R., Meyerson M., Gabriel S.B., Lander E.S., Getz G. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014, 505:495-501.
78. Wick D.A., Webb J.R., Nielsen J.S., Martin S.D., Kroeger D.R., Milne K., Castellarin M., Twumasi-Boateng K., Watson P.H., Holt R.A., Nelson B.H. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 2014, 20:1125-1134.
79. Tran E., Turcotte S., Gros A.a., Robbins P.F., Lu Y.C., Dudley M.E., Wunderlich J.R., Somerville R.P., Hogan K., Hinrichs C.S., et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014, 344:641-645.
80. Vigneron N., Van den Eynde B.J. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol 2012, 24:84-91.